Publications

5891 Results

Alliance A031501: AMBASSADOR study of Adjuvant Pembrolizumab (Pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) vs Observation (Obs): Extended follow-up results and metastatic disease recurrence distribution

Authors
A Apolo;K Ballman;G Sonpavde;S Berg;W Kim;R Parikh;M Teo;R Sweis;D Geynisman;P Grivas;G Chatta;Z Reichert;J Kim;M Bilen;B McGregor;S Srinivas;S Halabi;G Burbano;M Morris;J Rosenberg
Journal / Conference
ESMO (September 13-17, 2024, Barcelona, Spain), mini-oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/A031501

Development and Validation of a Risk Prediction Model for Acute Care Use among Advanced Cancer Patients on Clinical Trials

Authors
D Hershman;C Till;M LeBlanc;J Unger
Journal / Conference
ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), oral. JCO Oncol Pract 20, 277(2024) Volume 20, Number 10_suppl DOI: 10.1200/OP.2024.20.10_suppl.277
Year
2024
Research Committee(s)
Cancer Care Delivery

Radiation Target Nomenclature for Lymphoma Trials: Consensus Recommendations from the National Clinical Trials Network Groups

Authors
O Saifi;C Pinnix;L Ballas;C Kelsey;S Milgrom;S Terezakis;N Figura;R Parikh;J Grecula;S Flampouri;C Ha;A Lo;J Plastaras;D Hodgson;B Hoppe
Journal / Conference
Lancet Haematology Sep 30:S2352-3026(24)00276-X. doi: 10.1016/S2352-3026(24)00276-X. Online ahead of print
Year
2024
Research Committee(s)
Lymphoma

Nivolumab-AVD or Standard of Care in Advanced Stage Classic Hodgkin Lymphoma

Authors
A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;A Perry;A Kovach;D Hodgson;L Constine;L Kostakoglu Shields;A Prica;H Dillon;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg
Journal / Conference
New England Journal of Medicine Oct 17;391(15):1379-1389
Year
2024
Research Committee(s)
Lymphoma
PMID
PMID39413375
PMC
PMC11488644
Study Number(s)
S1826

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors

Authors
Y Chae;M Othus;S Patel;B Powers;C Hsueh;R Govindarajan;S Bucur;H Kim;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock
Journal / Conference
Journal for ImmunoTherapy of Cancer (JITC) Sep 28;12(9):e009128
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID39343510
PMC
PMC11440191
Study Number(s)
S1609

Circulating tumor cell (CTC) count is prognostic of overall survival in metastatic hormone sensitive prostate cancer (mHSPC)

Authors
A Goldkorn;C Tangen;M Plets;D Bsteh;T Xu;J Pinski;S Ingles;T Triche;G MacVicar;D Vaena;A Crispino;D McConkey;P Lara;M Hussain;D Quinn;T Dorff;IM Thompson;N Agarwal
Journal / Conference
JAMA Network Open Oct 1;7(10):e2437871
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID39374015
PMC
PMC11581504
Study Number(s)
S1216

SWOG/NCI S1609 Phase II Basket Trial Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer

Authors
Y Chae;M Othus;S Patel;K Wilkinson;E Whitman-Purves;J Lea;J Schallenkamp;N Adra;L Appleman;M Alden;J Thomes Pepin;J Ellerton;A Poklepovic;A Walter;M Rampurwala;W Robinson;L Il-Young Chung;H Kim;C McLeod;G Lopez;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
Clinical Cancer Research Oct 17. doi: 10.1158/1078-0432.CCR-24-0606. Online ahead of print
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID39417692
Study Number(s)
S1609

DNA Damage Response Gene Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial

Authors
G Iyer;C Tangen;M Sarfaty;A Regazzi;I Lee;M Fong;W Choi;C Dinney;T Flaig;I Thompson;S Lerner;D McConkey;J Rosenberg
Journal / Conference
JCO Precision Oncology Nov:8:e2400287. doi: 10.1200/PO.24.00287. Epub 2024 Nov 5. 2024
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1314

Navigating the Interplay of Cancer, Hemostasis, and Thrombosis: Investigating Tissue Factor in Colorectal Cancer

Authors
S Algaze;Y Yang;J Millstein;F Battaglin;S Soni;P Mittal;K Ashouri;A Wong;P Jayachandran;H Arai;J Lo;W Zhang;L Torres-Gonzalez;H Liebman;H-J Lenz
Journal / Conference
ICTHIC Meeting (May 17-19, 2024, Bergamo, Italy)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Development and validation of the RSClinN+ tool that integrates the 21-gene recurrence score and clinical variables to predict prognosis and chemotherapy benefit for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer

Authors
L Pusztai;J Hoag;K Albain;W Barlow;S Stemmer;A Meisner;G Hortobagyi;S Shak;J Rae;R Baehner;P Sharma;K Kalinsky
Journal / Conference
Journal of Clinical Oncology Dec 2:JCO2401507. doi: 10.1200/JCO-24-01507. Online ahead of print
Year
2024
Research Committee(s)
Breast
PMID
PMID39621968
Study Number(s)
S1007, SWOG-8814